Ozempic vs Wegovy: What's Different When It's the Same Molecule

Ozempic and Wegovy are the same molecule: semaglutide, made by Novo Nordisk^[1,2]. What differs is what each one is approved for and how high the dose goes. In the US, Ozempic is approved for type 2 diabetes, including lowering heart and kidney risk in people with diabetes, up to 2 mg a week^[1]. Wegovy is approved for weight management, for lowering heart risk in people with heart disease and obesity or overweight, and for a form of fatty liver disease^[2]. Its usual dose is 2.4 mg a week, up to 7.2 mg for weight in adults, and it also comes as a daily pill^[2].

Label facts have a dotted underline and the date I checked them against the US labels on DailyMed. The comparison with tirzepatide is in Ozempic vs. Mounjaro, and how the drug family works in what GLP-1 medications are.

Ozempic vs. Wegovy at a glance

Sources: sections 1, 2 and 3 of the US labels for Ozempic^[1], Wegovy^[2] and Rybelsus and Ozempic tablets^[3]; approval dates from Drugs@FDA for Ozempic^[4], Wegovy injection^[5] and Wegovy tablets^[6]. Prices: Novo Nordisk’s NovoCare pages, explained below^[19,20].

Why one molecule has two brand names

Each brand went through its own FDA application, backed by its own trials. Ozempic was approved in 2017 for type 2 diabetes^[4]. Wegovy was approved in 2021 for weight management, at a higher dose, 2.4 mg, tested in the STEP trials^[2,5]. Heart risk reduction followed in March 2024^[7], the 7.2 mg Wegovy HD pen in March 2026^[8], and the daily Wegovy pill in December 2025^[6].

So each brand carries its own label, list price and entry on insurance formularies. Medicare shows why that matters:

• The law. Medicare Part D can’t cover drugs used specifically for obesity, as KFF explains^[11]. Once Wegovy gained its heart-risk use in 2024, CMS let Part D plans cover it for that use, because it isn’t weight loss^[11].
• Diabetes goes through the regular plan. Type 2 diabetes and MASH are handled by a person’s regular Part D plan, according to CMS^[10].
• The temporary bridge. From July 1, 2026, to December 31, 2027, the CMS Medicare GLP-1 Bridge covers all forms of Wegovy (plus Zepbound KwikPen and Foundayo) for weight management in eligible adults, with a $50 copay. Ozempic isn’t on that list^[10].

Private plans set their own rules. Your plan’s formulary shows which brand it covers, and for which use.

Doses, pens and the Wegovy pill

Both injections start at the same 0.25 mg once weekly for 4 weeks^[1,2], then go up in steps. From there, the labels part ways:

Source: sections 2 and 3 of the US labels for Ozempic^[1] and Wegovy^[2].

The pills add a twist. The Wegovy pill goes up to 25 mg once daily, for weight and heart risk in adults^[2]. Ozempic tablets, for type 2 diabetes, come in 1.5, 4 and 9 mg^[3]. Their label says Rybelsus and Ozempic tablets are not substitutable on a mg-to-mg basis^[3], a reminder that milligrams don’t translate between semaglutide products. Your prescriber decides the product, the dose and any change. More on the pill in the Wegovy pill.

What each brand was tested for

The two brands rest on different trial programs: SUSTAIN (and FLOW) for type 2 diabetes, STEP and SELECT for weight and heart risk^[1,2]. Same molecule, but the numbers aren’t interchangeable, because the people, doses and lengths differ.

Ozempic: type 2 diabetes, heart and kidneys

• Blood sugar. In a 30-week trial of Ozempic alone (388 adults), the label reports HbA1c changes of −1.4 and −1.6 points on 0.5 and 1 mg vs. −0.1 on placebo, and weight changes of −3.8 and −4.7 kg vs. −1.2 kg^[1]. HbA1c reflects average blood sugar over the past few months.
• Heart. In SUSTAIN-6 (3,297 adults with type 2 diabetes at high cardiovascular risk, about 2 years), a heart attack, stroke or cardiovascular death happened in 6.6% on semaglutide 0.5 or 1 mg vs. 8.9% on placebo (hazard ratio 0.74; 95% CI 0.58 to 0.95) (paper)^[12].
• Kidneys. In FLOW (3,533 adults with type 2 diabetes and chronic kidney disease, median 41 months), the label reports that Ozempic 1 mg lowered the risk of the combined kidney and cardiovascular outcome (hazard ratio 0.76; 95% CI 0.66 to 0.88)^[1].

Wegovy: weight, heart risk and the pill

• STEP 1 (1,961 adults without diabetes, 68 weeks). Weight changed by −14.9% on 2.4 mg vs. −2.4% on placebo (paper)^[13].
• STEP 2 (1,210 adults with type 2 diabetes, 68 weeks). Weight changed by −9.6% on 2.4 mg vs. −3.4% on placebo (paper)^[14]. It’s the one trial that also had a 1 mg group, one of Ozempic’s doses, though comparing the two doses wasn’t its main goal^[14].
• STEP UP (1,407 adults with obesity, no diabetes, 72 weeks). Weight changed by −18.7% on 7.2 mg, −15.6% on 2.4 mg and −3.9% on placebo (paper)^[15].
• SELECT (17,604 adults with heart disease and a BMI of 27 or more, without diabetes, mean follow-up 39.8 months). A heart attack, stroke or cardiovascular death happened in 6.5% on 2.4 mg vs. 8.0% on placebo (hazard ratio 0.80; 95% CI 0.72 to 0.90) (paper)^[16].
• OASIS 4 (307 adults without diabetes, 64 weeks). The 25 mg pill changed weight by −13.6% vs. −2.2% on placebo (paper)^[17].

Novo Nordisk funded SUSTAIN-6, the STEP trials, SELECT and OASIS 4^{[12,13,14,15,16,17]}. The weight results sit side by side in the trial results chart, and what they mean in practice in how much weight people lose on GLP-1 medications. How Wegovy compares with tirzepatide is in Zepbound vs. Wegovy.

Side effects: same molecule, higher doses

Each label has its own table from its own placebo-controlled trials. Ozempic’s comes from two type 2 diabetes trials averaging about 33 weeks of treatment^[1]. Wegovy’s comes from weight-management trials of up to 68 weeks (2.4 mg) and 72 weeks (7.2 mg)^[2]. Read the columns as context by population and dose, not as a ranking:

Source: section 6.1 of the US labels for Ozempic (Table 1)^[1] and Wegovy (Tables 3 and 4)^[2]. The 7.2 mg table lists only effects more common on 7.2 mg than on both 2.4 mg and placebo^[2].

The one trial that tested both brand doses in the same people is STEP 2: digestive side effects affected 63.5% on 2.4 mg, 57.5% on 1 mg and 34.3% on placebo, mostly mild or moderate (paper)^[14]. The Ozempic label notes that most reports of nausea, vomiting or diarrhea happened during dose increases^[1].

The warnings overlap. Both carry the same boxed warning: thyroid C-cell tumors in rodents, of unknown relevance to humans, and a contraindication in people with a personal or family history of medullary thyroid carcinoma or with MEN 2^[1,2]. Both warn about acute pancreatitis, gallbladder disease, low blood sugar, kidney injury from dehydration, severe digestive reactions, diabetic retinopathy complications and aspiration during anesthesia or deep sedation^[1,2]. The Wegovy label adds a warning on heart rate increase^[2].

If digestive side effects are the problem, I have guides on what to eat with nausea and on constipation. Anything that worries you is worth raising with your doctor.

List prices, and why I don’t rank them

Novo Nordisk’s NovoCare pages list these prices, which I checked on September 24, 2026^[19,20]. The pages give no date for them. A list price is the price the manufacturer sets before discounts or rebates.

• Ozempic: $1,027.51 per pen, the same for every strength^[19].
• Wegovy: $1,349.02 per package, the same for the Wegovy pen, the Wegovy HD pen and the Wegovy pill^[20].

A pen of Ozempic and a package of Wegovy don’t hold the same doses, so these figures don’t compare one to one. Novo Nordisk itself notes that most people with insurance that covers the drug don’t pay list price, and that out-of-pocket cost depends on coverage^[19,20]. I don’t rank them by price: they’re approved for different conditions. The monthly cost calculator shows the math per dose, every 4 weeks and per year, with each price’s source and date.

Can you switch between Ozempic and Wegovy?

That’s a decision for your prescriber. Neither injection label describes switching from Ozempic to Wegovy or back^[1,2]. The Wegovy label describes switching only between Wegovy injection and Wegovy tablets^[2]. And it says concomitant use with other semaglutide-containing products or with any other GLP-1 receptor agonist is not recommended^[2], so the two aren’t meant to be used together. Because the dose ranges and approved uses differ, a change of brand is something your prescriber weighs against your diagnosis and history.

What about compounded semaglutide?

Compounded semaglutide isn’t Ozempic or Wegovy. The FDA says compounded drugs aren’t FDA-approved, which means the agency doesn’t review them for safety, effectiveness or quality before they’re sold^[9]. It also warns that salt forms such as semaglutide sodium and semaglutide acetate are different active ingredients from the one in the approved drugs^[9]. As of May 31, 2026, it had received 990 adverse event reports involving compounded semaglutide, including hospitalizations that may be linked to dosing errors^[9]. If you’re using or considering one, tell your doctor.

Frequently asked questions

Is Wegovy just a higher dose of Ozempic?

It’s the same molecule at a wider dose range, but not the same product. Wegovy goes up to 2.4 mg as the usual dose and 7.2 mg for weight in adults, with its own pens, a daily pill and different approved uses^[2]. Ozempic stops at 2 mg once weekly^[1].

Is Ozempic approved for weight loss?

Not in the US. Its label covers type 2 diabetes, including heart and kidney risk in people with diabetes^[1]. Weight did go down in its diabetes trials: in the 30-week trial above, −3.8 and −4.7 kg on 0.5 and 1 mg^[1]. Which product fits a given person is for their prescriber to decide.

Can people with type 2 diabetes take Wegovy?

Wegovy’s weight-management use isn’t limited to people without diabetes, and STEP 2 tested it in adults with type 2 diabetes^[14]. The label asks prescribers to monitor blood glucose before starting and during treatment in patients with diabetes^[2]. Your doctor decides which label fits your situation.

Which one lowers heart risk?

Both have a heart-risk use, for different people. Ozempic’s covers adults with type 2 diabetes and established cardiovascular disease^[1], based on SUSTAIN-6. Wegovy’s covers adults with established cardiovascular disease and either obesity or overweight^[2], based on SELECT, which excluded people with diabetes^[16].

What is Wegovy HD?

It’s the 7.2 mg single-dose Wegovy pen^[2], approved on March 19, 2026^[8]. The label reserves 7.2 mg for weight management in adults who already tolerate 2.4 mg^[2]. In STEP UP it lowered weight by 18.7%, vs. 15.6% on 2.4 mg^[15], with more tingling and skin sensitivity^[2] (see the table above).

Is the Wegovy pill the same as Rybelsus or Ozempic tablets?

Same molecule, different products. Rybelsus (3, 7 and 14 mg) and Ozempic tablets (1.5, 4 and 9 mg) are for type 2 diabetes^[3]. The Wegovy pill (1.5, 4, 9 and 25 mg) is for weight and heart risk^[2]. Their labels are separate, and the shared Rybelsus and Ozempic tablets label warns that those two can’t be swapped milligram for milligram^[3].

What happens if you stop semaglutide?

On average, much of the weight comes back. In the STEP 1 extension, a year after stopping semaglutide 2.4 mg, people had regained about two-thirds of what they’d lost (paper)^[18]. More in what happens when you stop a GLP-1 medication. Stopping is a decision to make with your doctor.